Roche to cut costs across group, coy on job cut numbers
Roche to cut costs across group, coy on job cut numbers
Dissident Elan shareholder to propose new board directors
Dissident Elan shareholder to propose new board directors
Takeda and Orexigen sign $1 billion obesity pact
Takeda and Orexigen sign $1 billion obesity pact
70% rise in Americans using five or more Rx drugs per month
70% rise in Americans using five or more Rx drugs per month
Pfizer to buy FoldRx Pharma
Pfizer to buy FoldRx Pharma
Allergan pays $600M to settle Botox illegal promotion case
Allergan pays $600M to settle Botox illegal promotion case
Merck/Cardiome heart drug OK in Europe
Merck/Cardiome heart drug OK in Europe
Nycomed launches COPD drug Daxas in Germany
Nycomed launches COPD drug Daxas in Germany
Genzyme CEO will sell but only at right price - Reuters
Genzyme CEO will sell but only at right price - Reuters
FDA wants even more info on AstraZeneca's RSV drug
FDA wants even more info on AstraZeneca's RSV drug
Tumor location breakthrough in breast cancer research
Confusion over the location of breast cancers may have led to avoidable deaths and the prescribing of inappropriate treatments, according to new research.
Psychosis patients' art to be exhibited
The Bethlem Tapestry, featuring the work of patients at the Bethlem Royal Hospital’s Psychosis Unit, will be unveiled in an exhibition for World Mental Health Day 2010 on 10 October.
Osteoporosis medication 'doubles cancer risk'
People who take oral bisphosphonates for osteoporosis over five years may be doubling their risk of developing oesophageal cancer, according to a UK study published online in the BMJ.
Oesophagus cancer link to osteoporosis drug
Long-term use of oral bisphosphonates, a drug used to treat osteoporosis in post-menopausal women, may double the risk of developing oesophagus cancer, research suggests.
Oesophageal cancer rising in men
Oesophageal cancer rates in men have risen by 50 per cent over the last 25 years, according to a study by Cancer Research UK.
|